Krystal Biotech Announces First Quarter 2022 Financial Results and Reports Updates on Operational Progress
New GEM-3 Phase 3 results for B-VEC were presented at the 2022 American Academy of Dermatology Annual Meeting.
- New GEM-3 Phase 3 results for B-VEC were presented at the 2022 American Academy of Dermatology Annual Meeting.
- Financial results for the quarter ended March 31, 2022:
Cash, cash equivalents, and investments totaled $468.0 million on March 31, 2022. - General and administrative expenses for the first quarter ended March 31, 2022 were $15.9 million, compared to $8.2 million for first quarter 2021.
- For additional information on the Companys financial results for the first quarter ended March 31, 2022, refer to form 10-Q filed with the SEC.